Andrew R Reynolds
Molecular Biology · 2014
A researcher in the Science corpus: 1 paper; trusts 5 researchers and is trusted by 1 researcher here, as inferred from the citation graph.
Subfields
- Molecular Biology — 44 citations into it; #11,051 of 17,773 by trust here, #16,527 by citations
- Oncology — 33 citations into it; #866 of 1,698 by trust here, #1,608 by citations
- Cancer Research — 27 citations into it
Whom Andrew R Reynolds trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
Who trusts Andrew R Reynolds overall
Papers from Andrew R Reynolds's perspective
Ordered by how strongly the researchers Andrew R Reynolds trusts endorse each paper. Same corpus, a different order for every researcher.
- Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. (New England Journal of Medicine)
- Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. (New England Journal of Medicine)
- Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis (Cancer Cell)
- Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy (Nature Medicine)
- Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy (Science)
- Microenvironmental regulation of metastasis (Nature Reviews. Cancer)
- Molecular mechanisms and clinical applications of angiogenesis (Nature)
- Glioblastoma stem-like cells give rise to tumour endothelium (Nature)
- Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. (Cell)
- PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment. (Cancer Cell)